BioCentury
ARTICLE | Clinical News

Methylnaltrexone regulatory update

July 25, 2016 7:00 AM UTC

FDA approved an NDA from Valeant for oral Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Valeant expects to launch the drug this quarter. The approval triggered a $50 million milestone payment to Progenics from Valeant, which gained worldwide rights to Relistor, excluding Japan, through its 2015 acquisition of Salix Pharmaceuticals Ltd. Salix had rights to the product from Progenics under a 2011 deal. ...